2-methylhexahydroimidazo[1,5-a]pyridin-3(2H)-one | 116605-65-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂卓
• 英文名称: 2-methylhexahydroimidazo[1,5-a]pyridin-3(2H)-one
• 英文别名: 2-Azamethyl-3-oxo-indolizidin；2-methyl-hexahydro-imidazo[1,5-a]pyridin-3-one；2-Methyl-1,5,6,7,8,8a-hexahydroimidazo[1,5-a]pyridin-3-one
• CAS: 116605-65-3
• 化学式: C₈H₁₄N₂O
• 分子量: 154.212
• InChiKey: SSXKVEFICDSJFM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.4
• 重原子数：
  11
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.88
• 拓扑面积：
  23.6
• 氢给体数：
  0
• 氢受体数：
  1

文献信息

• [EN] PRODRUGS OF PHENOLIC TRPV1 AGONISTS IN COMBINATION WITH LOCAL ANESTHETICS AND VASOCONSTRICTORS FOR IMPROVED LOCAL ANESTHESIA<br/>[FR] PROMÉDICAMENTS À BASE D'AGONISTES DE TRPV1 PHÉNOLIQUES EN ASSOCIATION AVEC DES ANESTHÉSIQUES LOCAUX ET DES VASOCONSTRICTEURS POUR AMÉLIORER UNE ANESTHÉSIE LOCALE
  申请人：CONCENTRIC ANALGESICS INC

  公开号：WO2017205534A1

  公开（公告）日：2017-11-30

  Described herein are compounds, pharmaceutical compositions and medicaments that include such compounds, and methods of using such compounds to modulate transient receptor potential vanilloid 1 receptor (TRPV1) activity.

  本文描述了包括这些化合物的化合物、药物组合物和药物，并使用这些化合物调节瞬时受体电位香草醛1受体（TRPV1）活性的方法。
• Prodrugs of phenolic TRPV1 agonists in combination with local anesthetics and vasoconstrictors for improved local anesthesia
  申请人：CONCENTRIC ANALGESICS, INC.

  公开号：US10821105B2

  公开（公告）日：2020-11-03

  Described herein are compounds, pharmaceutical compositions and medicaments that include such compounds, and methods of using such compounds to modulate transient receptor potential vanilloid 1 receptor (TRPV1) activity.

  本文描述了包括此类化合物的化合物、药物组合物和药剂，以及使用此类化合物调节瞬时受体电位香草素 1 受体（TRPV1）活性的方法。
• PRODRUGS OF PHENOLIC TRPV1 AGONISTS IN COMBINATION WITH LOCAL ANESTHETICS AND VASOCONSTRICTORS FOR IMPROVED LOCAL ANESTHESIA
  申请人：Concentric Analgesics, Inc.

  公开号：EP3463576A1

  公开（公告）日：2019-04-10
• PHARMACEUTICAL COMPOSITION COMPRISING A LACTAM OR BENZENESULFONAMIDE COMPOUND
  申请人：Kato Issei

  公开号：US20120135997A1

  公开（公告）日：2012-05-31

  The present invention provides, for example, the following compounds as a pharmaceutical composition for treating diseases induced by production, secretion or deposition of amyloid β proteins. The present invention provides a pharmaceutical composition for suppressing amyloid β production comprising a compound of the formula: wherein A is a benzene ring, a pyridine ring or a pyrimidine ring, X is sultam, lactam, sulfonamide or the like, C is substituted or unsubstituted imidazolyl, substituted or unsubstituted oxazolyl or the like, R 2 , R 3 and R 4 are each independently hydrogen, halogen, hydroxy, carboxy, substituted or unsubstituted alkyl, substituted or unsubstituted alkoxy or the like, its pharmaceutically acceptable salt or a solvate thereof.
• UREA, AMIDE, AND SUBSTITUTED HETEROARYL COMPOUNDS FOR CBL-B INHIBITION
  申请人：Nurix Therapeutics, Inc.

  公开号：US20220387395A1

  公开（公告）日：2022-12-08

  Compounds of formulae (I) and (II), compositions, and methods for use in inhibiting the E3 enzyme Cbl-b in the ubiquitin proteasome pathway are disclosed. The compounds, compositions, and methods can be used to modulate the immune system, to treat diseases amenable to immune system modulation, and for treatment of cells in vivo, in vitro, or ex vivo.